8G2M
The tumor activated anti-CTLA-4 monoclonal antibody XTX101 demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
Summary for 8G2M
Entry DOI | 10.2210/pdb8g2m/pdb |
Descriptor | masking peptide, Heavy chain of humanized IgG, Light chain of humanized IgG, ... (5 entities in total) |
Functional Keywords | engineered antibody, immune system |
Biological source | Mus musculus More |
Total number of polymer chains | 3 |
Total formula weight | 47103.47 |
Authors | |
Primary citation | Jenkins, K.A.,Park, M.,Pederzoli-Ribeil, M.,Eskiocak, U.,Johnson, P.,Guzman, W.,McLaughlin, M.,Moore-Lai, D.,O'Toole, C.,Liu, Z.,Nicholson, B.,Flesch, V.,Qiu, H.,Clackson, T.,O'Hagan, R.C.,Rodeck, U.,Karow, M.,O'Neil, J.,Williams, J.C. XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer. J Immunother Cancer, 11:-, 2023 Cited by PubMed: 38164757DOI: 10.1136/jitc-2023-007785 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.8 Å) |
Structure validation
Download full validation report